(-)-N-(1-benzyloxy-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-yl)-4-(4-chloro-phenoxy)-N-(2-morpholin-4-yl-ethyl)-benzenesulfonamide | 1020104-48-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (-)-N-(1-benzyloxy-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-yl)-4-(4-chloro-phenoxy)-N-(2-morpholin-4-yl-ethyl)-benzenesulfonamide
• 英文别名: N-(1-Benzyloxy-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-(R)-yl)-4-(4-chloro-phenoxy)-N-(2-morpholin-4-yl-ethyl)-benzenesulfonamide；4-(4-chlorophenoxy)-N-(2-morpholin-4-ylethyl)-N-[(6R)-7-oxo-1-phenylmethoxy-5,6-dihydro-2H-azepin-6-yl]benzenesulfonamide
• CAS: 1020104-48-6
• 化学式: C₃₁H₃₄ClN₃O₆S
• 分子量: 612.146
• InChiKey: YVIXLFIWOVUJOX-SSEXGKCCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  42
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  97
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (-)-N-(1-benzyloxy-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-yl)-4-(4-chloro-phenoxy)-N-(2-morpholin-4-yl-ethyl)-benzenesulfonamide 在 甲烷磺酸 作用下， 反应 20.0h， 生成 (-)-4-(4-chloro-phenoxy)-N-(1-hydroxy-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-yl)-N-(2-morpholin-4-yl-ethyl)-benzenesulfonamide
  参考文献：
  名称：

  HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS

  摘要：

  这项发明提供了一种新颖的杂环衍生物基质金属蛋白酶抑制剂的化学式，以及包含同样化合物的药物组合物，用于治疗通过拮抗基质金属蛋白酶而改善的疾病。该发明还提供了使用即时药物组合物的治疗和预防方法。

  公开号：

  US20080103129A1
• 作为产物：
  描述：

  O-苄基羟胺 在 N-甲基吗啉 、 吡啶 、 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 N-羟基-7-氮杂苯并三氮唑 、 caesium carbonate 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 154.5h， 生成 (-)-N-(1-benzyloxy-2-oxo-2,3,4,7-tetrahydro-1H-azepin-3-yl)-4-(4-chloro-phenoxy)-N-(2-morpholin-4-yl-ethyl)-benzenesulfonamide
  参考文献：
  名称：

  Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy

  摘要：

  The discovery of potent N-hydroxyl caprolactam matrix metalloproteinase (MMP) inhibitors (6) based on the natural product Cobactin-T (2) is described. The synthetic method, which utilizes the ring closing metathesis reaction, is compatible to provide complementary (R) and (S) enantiomers. These compounds tested against MMP-2 and 9, show that the R stereochemistry (i.e., 16), which is opposite for that found in the natural product Cobactin-T is >1000-fold more active with IC(50) values of 0.2-0.6 nM against both enzymes. The variation in the incorporation of the sulfonamide enzyme recognition element (Ar(2)XAr(1)SO(2)N(R(1)), 6), along with alterations in the RCM/double bond chemistry (R(2)) provided a series of sub nanomolar MMP inhibitors. For example, compounds 16 and 34 were found to be the most potent with IC(50) values against MMP-2 and MMP-9 found to be between 0.2 and 0.6 nM with 34 being the most potent compound discovered (MMP-2 IC(50) = 0.39 nM and MMP-9 IC(50) = 0.22 nM). Compounds 16 and 34 showed acceptable drug-like properties in vivo with compound 34 showing oral bioavailability. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.068

文献信息

• Heterocyclic derived metalloprotease inhibitors
  申请人：Janssen Pharmaceutica NV

  公开号：US07803793B2

  公开（公告）日：2010-09-28

  This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula: and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.

  该发明提供了一种新型杂环衍生物基质金属蛋白酶抑制剂，其化学式为：以及包含其的制药组合物，用于治疗通过拮抗基质金属蛋白酶改善的疾病。此发明还提供了使用上述制药组合物的治疗和预防方法。
• US7803793B2
  申请人：——

  公开号：US7803793B2

  公开（公告）日：2010-09-28